

Table 2: Detailed information about the demographic, clinical features, ocular examination findings, and treatment plans of patients with diabetic retinopathy whose treatment is delayed due to the Covid 19 pandemic.

No, Gender, Age (years)	Last Hb A1c * (%)	Current Hb A1c ** (%)	Laterality	Previous treatments (number of IV injections)	Pre-pandemic visit frequency (days), total number of visits	Elapsed time after last visit (days)	Last BCVA at pre-pandemic examination (RE/LE) (logMar) CMT (μm) (RE/LE)	Current BCVA (RE/LE) (logMar) CMT (μm) (RE/LE)	Current ocular examination results	Planned treatment
1, F, 67	6.2	6.7	Bilateral	RE: IV injection (4) LE: IV injection (5)	38.6 (7)	126	0.2 / 0.3 274 / 229	0.3 / 1.3 278 / 835	LE: DME	LE: IV injection
2, M, 56	7.2	7.8	Bilateral	RE: IV injection (3)+ Panretinal Laser LE: IV injection (2)+ Panretinal Laser	42.4 (5)	97	0.4 / 0.5 333 / 498	1.3 / 0.7 603 / 521	Bilateral: DME	Bilateral: IV injection + Panretinal Laser
3, F, 58	6.7	8.8	Unilateral	LE: IV injection (5)	41.1 (7)	104	0.1 / 0.3 251 / 339	0.1 / 0.7 265 / 454	LE: DME	LE: IV injection
4, M, 61	8.7	8.4	Bilateral (RE: NVG)	RE: IV injection (9)+ Panretinal Laser LE: IV injection (7)+ Panretinal Laser	34.3 (13)	92	- / 0.5 -/ 288	- / 1.0 -/ 346	LE: DME	LE: IV injection
5, F, 60	8.6	7.7	Bilateral	RE: IV injection (3)+ Panretinal Laser LE: IV injection (4)+ Panretinal	39.7 (6)	128	0.5 / 0.5 545 / 549	1.0 / 1.0 652 / 668	Bilateral: DME	Bilateral: IV injection

				Laser						
6, F, 64	10.4	8.3	Bilateral	RE: IV injection (5)+ Panretinal Laser LE: IV injection (4)+ Panretinal Laser	52.3 (7)	135	1.3 / 1.3 345 / 306	1.6 / 1.5 - / 486	RE: VH LE: DME	RE: PPV LE: IV injection
7, M, 57	8.7	7.8	Bilateral	RE: IV injection (2)+ Panretinal Laser LE: IV injection (3)+ Panretinal Laser	44.3 (4)	103	0.2 / 0.5 254 / 296	0.3 / 1.3 304 / 442	Bilateral: DME	RE: IV injection+ Panretinal Laser LE: IV injection
8, M, 71	6.3	6.7	Bilateral	RE: IV injection (7)+ Panretinal Laser LE: IV injection (5)+ Panretinal Laser	48.6 (10)	112	0.2 / 0.2 242 / 238	0.4 / 0.2 314 / 248	RE: DME	RE: IV injection
9, F, 63	9.4	7.2	Unilateral	LE: IV injection (1)	48.5 (2)	129	0.2 / 0.4 236 / 276	0.3 / 0.4 334 / 298	Bilateral: DME	Bilateral: IV injection
10, F, 67	8.1	11.7	Bilateral	RE: IV injection (5)+ Panretinal Laser LE: IV injection (6)+ Panretinal Laser	56.7 (9)	132	1.5 / 1.3 -/ 312	1.6 / 1.3 -/ 352	RE: VH LE: DME	RE: PPV LE: IV injection
11, M, 74	7.2	6.9	Unilateral	RE: IV injection (2)	46.7 (3)	95	0.3 / 0.2 262 / 254	0.5 / 0.2 336 / 248	RE: DME	RE: IV injection
12, F, 60	8.8	8.0	Unilateral	LE: IV injection (2)	38.5 (4)	117	0.1 / 0.4 232 / 287	0.2 / 0.7 268 / 298	Bilateral: DME	Bilateral: IV injection LE: Panretinal laser

13, M, 72	7.5	6.9	Bilateral	RE: IV injection (4) LE: IV injection (3)	45.3 (6)	99	0.3 / 0.2 246 / 234	0.5 / 0.3 354 / 246	RE: DME	RE: IV injection
14, F, 60	10.2	7.8	Bilateral	RE: IV injection (3) LE: IV injection (2)	50.3 (4)	92	0.3 / 0.5 284 / 322	0.7 / 0.7 414 / 406	Bilateral: DME	Bilateral IV enjeksiyon
15, M, 57	8.8	8.1	Unilateral	LE: IV injection (6)	46.1 (8)	124	0.2 / 0.3 238 / 226	0.2 / 0.7 234 / 306	LE: DME	LE: IV injection
16, F, 64	12.1	9.4	Bilateral	RE: IV injection (4)+ Panretinal Laser LE: IV injection (3)+ Panretinal Laser	49.8 (5)	128	0.4 / 0.4 304 / 264	1.6 / 1.3 - / 457	RE: VH LE: DME	RE: PPV LE: IV injection
17, F, 60	10.4	7.2	Bilateral	RE: IV injection (2) LE: IV injection (2)	50.7 (3)	106	0.2 / 0.3 281 / 296	0.7 / 0.5 344 / 302	Bilateral: DME	Bilateral: IV injection

F: Female **M:** Male **Hb A1c:** Hemoglobin A1c **IV:** Intravitreal

BCVA: Best-corrected visual acuity **RE:** Right Eye **LE:** Left Eye

CMT: Central macular thickness **µm:** micron meter **NVG:** Neovascular glaucoma

DME: Diabetic macular edema **VH:** Vitreous hemorrhage **PPV:** Pars plana vitrectomy

***:** HbA1c values before the pandemic period

****:** HbA1c values during the pandemic period